文献速递肝病消化道肿瘤与早癌

肝细胞癌中干细胞样CCR4+调节性T细胞编排免疫抑制微环境

Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
PubMed 文献 · J Hepatol · 2021-09-12

该研究探讨肿瘤浸润CCR4+调节性T细胞(Treg)在乙型肝炎相关肝细胞癌(HCC)中的作用。CCR4+ Treg是HBV+ HCC中主要募集的Treg类型,与索拉非尼耐药和HBV载量相关,具有干细胞样特性并强效抑制CD8+ T细胞。靶向CCR4可阻断瘤内Treg积聚,克服索拉非尼耐药并使肿瘤对PD-1阻断敏感。

要点

  • CCR4+ Treg是HBV相关HCC中主要Treg亚群,与索拉非尼耐药和HBV载量相关。
  • CCR4+ Treg高表达IL-10和IL-35,具有PD-1+TCF1+干细胞样特性,强效抑制CD8+ T细胞。
  • CCR4拮抗剂或N-CCR4-Fc可阻断瘤内Treg积聚,克服索拉非尼耐药并增敏PD-1阻断。

核心结论

  • 瘤内干细胞样CCR4+ Treg编排肿瘤微环境中的免疫抑制资源细胞。
  • 靶向CCR4可通过特异性阻断Treg浸润和抑制TIL-Treg池维持来增强抗肿瘤免疫。

研究设计与样本

  • 研究采用小鼠模型和临床样本,通过流式细胞术分析CCR4+ Treg。
  • 通过遗传和表观遗传学方法探究肿瘤浸润和诱导的CCR4+ Treg功能。
  • 开发N端重组CCR4蛋白(N-CCR4-Fc)作为中和伪受体阻断CCR4+ Treg趋化。
  • 通过肿瘤重量、生长动力学和生存曲线评估CCR4拮抗的免疫治疗疗效。

主要发现

  • CCR4+ Treg是HBV相关HCC中主要募集的Treg类型,与索拉非尼耐药和HBV载量滴度相关。
  • 与CCR4- Treg相比,CCR4+ Treg增加IL-10和IL-35表达,并增强抑制CD8+ T细胞的功能。
  • CCR4+ Treg显示PD-1+TCF1+干细胞样特性。
  • ATAC-seq数据显示肿瘤浸润Treg(TIL-Treg)与诱导Treg之间存在显著染色质重塑,提示长期染色质重编程导致CCR4+ TIL-Treg获得增强的免疫抑制干细胞样特异性。
  • CCR4拮抗剂或N-CCR4-Fc治疗阻断瘤内Treg积聚,克服索拉非尼耐药,并使肿瘤对PD-1检查点阻断敏感。

临床怎么用

  • 靶向CCR4可作为一种免疫治疗策略,通过特异性阻断Treg向肿瘤微环境浸润来增强抗肿瘤免疫。
  • CCR4拮抗剂或N-CCR4-Fc可能用于克服HCC对索拉非尼的耐药,并增敏PD-1检查点阻断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Regulatory T cell (Treg) depletion increases antitumor immunity. However, severe autoimmunity can occur following systemic loss of Tregs, which could be avoided by selectively depleting intratumoral Tregs. Herein, we aimed to investigate the role of tumor-infiltrating CCR4+ Tregs in hepatocellular carcinoma (HCC) and to provide a potential target strategy for immunotherapy. METHODS: CCR4+ Tregs were analyzed by flow cytometry in murine models and clinical samples. The function of tumor-infiltrating and induced CCR4+ Tregs was interrogated by genetic and epigenetic approaches. To block CCR4+ Treg chemotaxis, we developed an N-terminus recombinant protein of CCR4 (N-CCR4-Fc) as a neutralizing pseudo-receptor that effectively bound to its ligand CCL22. The efficacy of CCR4 antagonism as an immunotherapeutic agent was evaluated by tumor weights, growth kinetics and survival curves. RESULTS: CCR4+ Tregs were the predominant type of Tregs recruited to hepatitis B-associated HCC (HBV+ HCC), correlating with sorafenib resistance and HBV load titers. Compared with CCR4- Tregs, CCR4+ Tregs exhibited increased IL-10 and IL-35 expression, and enhanced functionality in suppressing CD8+ T cells. CCR4+ Tregs also displayed PD-1+TCF1+ stem-like properties. ATAC-seq data revealed substantial chromatin remodeling between tumor-infiltrating Tregs (TIL-Tregs) and induced Tregs, suggesting that long-term chromatin reprogramming accounted for the acquisition of enhanced immunosuppressive stem-like specificity by CCR4+ TIL-Tregs. Treatment with a CCR4 antagonist or N-CCR4-Fc blocked intratumoral Treg accumulation, overcame sorafenib resistance, and sensitized tumors to PD-1 checkpoint blockade. CONCLUSIONS: Intratumoral stem-like CCR4+ Tregs orchestrated immunosuppressive resource cells in the tumor microenvironment. CCR4 could be targeted to enhance antitumor immunity by specifically blocking infiltration of Tregs into the tumor microenvironment and inhibiting maintenance of the TIL-Treg pool. LAY SUMMARY: Targeting regulatory T cells is a promising approach in cancer immunotherapy; however, severe autoimmunity can occur following systemic regulatory T cell loss. This could be avoided by selectively depleting intratumoral regulatory T cells. Herein, targeting intratumoral stem-like CCR4+ regulatory T cells helped to overcome sorafenib resistance and sensitize tumors to immune checkpoint blockade in mouse models of liver cancer. This approach could have wide clinical applicability.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Gao Y, You M, Fu J, et al. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J Hepatol. 2021. PMID: 34689996. doi:10.1016/j.jhep.2021.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。